MedTrace Logo

Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (SELIC).

NCT07305363 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-04-09

No results posted yet for this study

Summary

A prospective, open-label, single-arm, investigator-initiated study (SELIC) to evaluate the efficacy and safety of seladelpar in adult liver transplant recipients with Ischemic cholangiopathy (IC).

Conditions

  • Liver Transplant; Complications
  • Ischemic Cholangiopathy

Interventions

DRUG

Seladelpar

Seladelpar is a selective peroxisome proliferator-activated receptor delta (PPAR-δ) agonist

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-09-30
Completion
2027-12-31
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07305363 on ClinicalTrials.gov